Last reviewed · How we verify
Sinemet Cr (CARBIDOPA)
Levodopa crosses the blood-brain barrier and is converted to dopamine in the brain, relieving Parkinson's disease symptoms.
Sinemet Cr (Carbidopa) is a small molecule aromatic amino acid decarboxylation inhibitor originally developed by Merck Sharp Dohme and currently owned by Aton. It targets lysine-specific demethylase 4E and is FDA-approved since 1975 for the treatment of Parkinson's disease, Parkinsonism, and Postencephalitic parkinsonism. As an off-patent medication, Sinemet Cr is available from multiple generic manufacturers. Key safety considerations include the potential for adverse effects such as nausea, dizziness, and orthostatic hypotension. Commercially, Sinemet Cr is widely available in the market.
At a glance
| Generic name | CARBIDOPA |
|---|---|
| Sponsor | Aton |
| Drug class | Aromatic Amino Acid [EPC] |
| Target | Lysine-specific demethylase 4E |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1975 |
Mechanism of action
Parkinson’s disease symptoms are caused by a lack of dopamine in the brain. Levodopa, which can cross the blood-brain barrier, is converted to dopamine in the brain, thereby alleviating these symptoms.
Approved indications
- Parkinson's disease
- Parkinsonism
- Postencephalitic parkinsonism
Common side effects
- Dyskinesia
- Nausea
- Hallucinations
- Confusion
- Dizziness
- Depression
- Urinary tract infection
- Headache
- Dream abnormalities
- Dystonia
- Vomiting
- Upper respiratory infection
Key clinical trials
- Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation (NA)
- [18F]F-DOPA Imaging in Patients With Autonomic Failure (PHASE1)
- Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease (PHASE2)
- Montelukast in Parkinson Disease (PHASE2,PHASE3)
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- Levodopa for Diabetic Retinopathy (PHASE2)
- A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants (PHASE1)
- Dopaminergic Dysfunction in Late-Life Depression (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sinemet Cr CI brief — competitive landscape report
- Sinemet Cr updates RSS · CI watch RSS
- Aton portfolio CI